Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia

Inclusion Criteria

• •1. Patients must have histologically or cytologically confirmed Acute Myeloid Leukemia, as defined by the WHO classification.
• •2. Patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease.
• •3. For patients who have received no prior conventional chemotherapy, one of the following must be present:
• •* Poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5, 11q23 abnormalities, inv\[3\])
• •* Secondary leukemia (prior hematologic disorder or therapy-related leukemia).
• •4. Age \> 60 years of age.
• •5. Life expectancy of greater than 3 months.
• •6. ECOG performance status greater than 2.
• •7. Patients must have normal organ and marrow function as defined below:
• •8. Adequate hepatic function: Total bilirubin 1.5mg/dL, AST(SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal.
• •9. Adequate renal function: serum creatinine within normal institutional limits or Calculated creatinine clearance \> 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
• •10. Ability to understand and the willingness to sign a written informed consent document.